Jazz Pharmaceuticals plc

NASDAQ:JAZZ  
136.68
-2.45 (-1.76%)
Products, Regulatory

Pharmamar And Jazz Pharmaceuticals Announce Initiation Of Confirmatory Phase 3 Clinical Trial Of Zepzelca® (Lurbinectedin) For The Treatment Of Patients With Relapsed Small Cell Lung Cancer

Published: 12/13/2021 07:40 GMT
Jazz Pharmaceuticals plc (JAZZ) - Pharmamar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients With Relapsed Small Cell Lung Cancer.
Jazz Pharmaceuticals Plc - Confirmatory Trial is Designed to Secure Full Approval in U.S. and Serve As a Registrational Trial for Ema.
Jazz Pharmaceuticals Plc - Multi-center, Open-label Global Trial Will Enroll 705 Patients From Over 100 Centers Mainly in North America and Europe.